Trial Profile

Crizotinb or Standard Chemotherapy in Met Exon 14 Skipping Advanced Non-small Cell Lung Cancer

Status: Recruiting

Phase of Trial: Phase II

Latest Information Update: 10 Jun 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Crizotinib (Primary) ; Savolitinib (Primary) ; Bevacizumab; Carboplatin; Pemetrexed
Indications Non-small cell lung cancer
Focus Therapeutic Use
Acronyms CONFIRM

Most Recent Events

01 Jun 2024 Savolitinib, Pemetrexed, Carboplatin, Bevacizumab drugs has been added to this study.
29 May 2024 Planned number of patients changed from 80 to 120, this study is now an prospective study.
29 May 2024 Planned End Date changed from 24 Mar 2025 to 24 Mar 2026.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com